Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 3Primary Myelofibrosis 2Leukemia, Neutrophilic, Chronic 1

Interventions

fludarabine phosphate 43Whole-Body Irradiation 36Mycophenolic Acid 36Peripheral Blood Stem Cell Transplantation 31Cyclophosphamide 31Tacrolimus 28Busulfan 22Antilymphocyte Serum 21Cyclosporine 19fludarabine 17ruxolitinib 16Melphalan 16Methotrexate 15Cytarabine 12thymoglobulin 9Sirolimus 9Etoposide 9Granulocyte Colony-Stimulating Factor 8Filgrastim 8Cyclosporins 8Radiotherapy 7Cord Blood Stem Cell Transplantation 7Rituximab 6Alemtuzumab 6merphos 5Stem Cell Transplantation 5Flow Cytometry 5Azacitidine 5sargramostim 4ponatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Myeloproliferative Disorders × fedratinib × Clear all
NCT05177211 2026-04-17

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Neutrophilic, Chronic

NCT03952039 2025-08-28

FREEDOM2

Celgene

Phase 3 Completed
202 enrolled 23 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03755518 2024-12-12

FREEDOM

Celgene

Phase 3 Terminated
38 enrolled 23 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡